Wedbush Securities has lowered its price target for Pyxis Oncology (PYXS) from $8 to $7, while reiterating an Outperform rating. This adjustment follows recent corporate and financial updates from the company, suggesting a slightly revised valuation outlook from the analyst firm.
Wedbush Securities adjusted its price target for Pyxis Oncology (PYXS) from $8 to $7, a 12.5% reduction. This change comes after the company's recent corporate and financial updates, which likely prompted Wedbush to reassess its valuation model. Despite the lower price target, the firm maintained its 'Outperform' rating, indicating continued confidence in the stock's potential to outperform the market, albeit with a slightly reduced upside. For traders, this could lead to short-term negative sentiment due to the lowered target, but the maintained 'Outperform' rating might temper significant selling pressure. The key risk is whether the market focuses more on the reduced target or the continued positive rating.